Navigation Links
Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
Date:3/9/2009

SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer's disease in the world.

The transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream. It will enable the number of doses to be reduced, make it easier to be used for patients with Alzheimer's disease who have difficulty in swallowing, and also reduce the burden of caregivers or family members when administering it to patients.

About Teikoku

Teikoku Pharma USA Inc. is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; chronic and acute Pain and CNS. Teikoku's main product is Lidoderm(R) (lidocaine 5% patch) for PHN (post herpetic neuralgia) , in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmBH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

Teikoku's commitment is to expand Trandermal technologies for the benefit of patients and partners. For more information, please visit www.teikokuusa.com

About Eisai

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, integrative oncology, and vascular/immunology reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. For more information, please visit www.eisai.co.jp .


'/>"/>
SOURCE Teikoku Pharma USA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IDM Pharmas MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
2. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
3. Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry
4. Victory Pharma Announces $45 Million Equity Financing
5. Children's Hospital Central California and CVS/Pharmacy Wheelchair Fund Featured in "Extreme Makeover: Home Edition"
6. Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing
7. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
8. Merz Aesthetics, a Division of Merz Pharmaceuticals USA, Introduces a Universal Language of Aging for Use in Education, Research and Practice
9. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
10. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
11. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... ... 2017 , ... Old School Labs™, makers of the wildly popular all-natural sports ... Ansley to its growing team of brand ambassadors. The Olympia top finisher and former ... than a year was able to turn professional, participating in the 2013 NPC USA ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the wilderness ... of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education at ... master’s degree in education in the field of curriculum and instruction. Kimberly’s passion for ...
(Date:1/22/2017)... FRANCE (PRWEB) , ... January 22, 2017 , ... Phytocéane ... Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired by ... used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create this ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
(Date:1/21/2017)... , Jan 20, 2017 Research ... Clinical Laboratory Testing Market By Type of Test (Tumor, Clinical ... & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), ... ... attractive destination for healthcare services, market segments, especially clinical lab ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
Breaking Medicine Technology: